ESG

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

BizClik announces its AI LIVE London Summit for 2026, aiming to cut through the hype with a focus on enterprise reality in a crowded global tech scene.

A validated dry EEG headset provides a scalable, objective measure of brain plasticity, promising to accelerate drug discovery for Alzheimer's and depression.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Iron Software funds biochar kilns in Chiang Mai, tackling an environmental crisis that threatens the city's 'mini Silicon Valley' status.

While US sales numbers declined in 2025, Mazda posted record CPO figures, earned top safety honors, and saw major growth in Canada and Mexico.

The fresh food packaging market is set to soar, but can it balance consumer demands for sustainability, safety, and convenience with the high costs of innovation?

United is set to reveal its full-year 2025 earnings, putting its ambitious growth strategy and market leadership claims to the ultimate test.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

A new joint venture between Corewell Health and Quest Diagnostics aims to reshape lab services across Michigan with a new high-tech facility and new efficiencies.

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

New AMA codes for PolarityBio's SkinTE signal a strategic step toward commercialization, aiming to ease clinical adoption for chronic wound care.